LanguaTalk

Surfing the MASH Tsunami

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL

S3-E60.3 - Madrigal Announcement on Resmetirom: Diving into Implications

15 mins; December 24, 2022

S3-E60.2 - Madrigal Announcement on Resmetirom: First Reactions and Differing Perspectives

15 mins; December 24, 2022

S3-E60.1 - Donna Cryer on the Far-Reaching Implications of Madrigal’s Emerging Story on Resmetirom

22 mins; December 24, 2022

S3-E61 - NASH-TAG 2023 Preview with Stephen Harrison

39 mins; December 23, 2022

S3-E60 - Madrigal Announces Breaking News: Positive Topline Results from Pivotal MAESTRO-NASH Trial of Resmetirom

82 hours 55 mins; December 21, 2022

S3-E59.3 - Year-End Interview with Donna Cryer

32 mins; December 18, 2022

S3- E59.2 - Year-End Interview with Hannes Hagström

27 mins; December 17, 2022

S3-E59.1 - Year-End Interview with Scott Friedman

26 mins; December 16, 2022

S3-E59 - 2022 NAFLD Year-in-Review Interview Series, Part 1

48 mins; December 15, 2022

S3-58.5 - From the Vault: Part 2: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.com

19 mins; December 11, 2022

S3-58.4 - From the Vault: Part 1: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.com

16 mins; December 11, 2022

S3-E58.3 - NAIL-NIT Retrospective Analysis and the Role of Consortia in Reshaping the Focus of NITs

16 mins; December 10, 2022

S3-E58.2 - Expanding Benefits in FibroScan Use and Integrating Digital Tools

14 mins; December 10, 2022

S3-E58.1 - Returning to In-Person Meetings and Emerging News on NICE and FibroScan

14 mins; December 10, 2022

S3-E58 - Surfing 2022: NAFLD Year-in-Review

44 mins; December 07, 2022

S3-E57.5 - From the Vault: “Seeing what Should Be” – Imaging the Liver To Assess Functioning Hepatocytes

10 mins; December 04, 2022

S3-E57.4 - Discussing Critical Success Factors for Placebo Cohorts

11 mins; December 04, 2022

S3-E57.3 - A Priori Placebo Response Rates and Challenges in Managing Samples Through Trials

11 mins; December 03, 2022

S3-E57.2 - Origins of the Liver Forum and Capturing the Richness of Data Emerging from NASH Studies

13 mins; December 03, 2022

S3-E57.1 - Veronica Miller on Traversing from the HIV Forum to the Liver Forum

13 mins; December 03, 2022

S3-E57 - The Liver Forum: Fighting Fatty Liver Using Collective Knowledge and Experience

55 mins; November 30, 2022

S3-E56.6 - From the Vault: Focus On NASH Cirrhosis: Trials in Process and a Plea For MRE

21 mins; November 27, 2022

S3-E56.5 - Improving Patient Self-Management and Key Takeaways on Nutrition for NASH Resolution

10 mins; November 27, 2022

S3-E56.4 - Integrated Solutions for Improved Patient Support

10 mins; November 27, 2022

S3-E56.3 - The Psychology of Decision-Making Around Diet and Professional Support

10 mins; November 26, 2022

S3-E56.2 - Setting and Driving Realistic Goals, and Dietician Visits as a Life-Long Therapy

10 mins; November 26, 2022

S3-E56.1 - Weight Reduction for NASH Resolution: Strategies for Long-Term Adherence to Lifestyle Modifications

10 mins; November 26, 2022

S3-E56 - Focus on the Intersection of Nutrition and NASH

57 mins; November 23, 2022

S3-E55.6 - From the Vault: #NASHDay 2022 Wrap-Up Panel: The Importance of #StopNASHNow

16 mins; November 20, 2022

S3-E55.5 - Pediatric and Lean NASH: Learning from Diverse Populations

12 mins; November 20, 2022

S3-E55.4 - Emerging Roles for ELF Test and Advances in Use of PPARs

11 mins; November 20, 2022

S3-E55.3 - NIT Efficacy in Primary Care and Diabetes Clinic Settings

15 mins; November 19, 2022

S3-E55.2 - Comparing Global Health Systems, Standardizing AST and Educating on NAFLD Prevalence

16 mins; November 19, 2022

S3-E55.1 - Insights from Fatty Liver Foundation’s Annual Survey of Patient Perspectives

11 mins; November 19, 2022

S3-E55 - 2022 AASLD Wrap-Up: Reviewing a Momentous Meeting

61 hours 7 mins; November 16, 2022

S3-E54.4 - An Interview with Michael Cooreman, CMO of Inventiva

30 mins; November 13, 2022

S3-E54.3 - Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study's Phase 3 Results

14 mins; November 13, 2022

S3-E54.2 - Presentation on Efruxifermin in NASH with Fibrosis

17 mins; November 13, 2022

S3-E54.1 - Utilizing Best Practices in Diagnostics

13 mins; November 13, 2022

S3-E53.3 - Pan-Society Presentation of NAFLD Nomenclature Consensus Process

20 mins; November 12, 2022

S3-E53.2 - Serum Metabolomics, Gene Therapy and the Waning Future of Biopsy

16 mins; November 12, 2022

S3-E53.1 - The Gut Microbiome and Complexities of NAFLD

20 mins; November 12, 2022

S3-E54 - AASLD 2022 Liver Meeting Live Coverage: Part 2

94 hours 11 mins; November 09, 2022

S3-E53 - AASLD 2022 Liver Meeting Live Coverage: Part 1

47 mins; November 07, 2022

S3-E52.6 - From the Vault: AASLD 2021: The Path To Making NITs the “Gold Standard” for Drug Trials

12 mins; November 06, 2022

S3-E52.5 - 2022 AASLD Preview: Final Thoughts

9 mins; November 06, 2022

S3-E52.4 - Exploring the NAFLD-Metabolic Link Through Screening Tools

12 mins; November 06, 2022

S3-E52.3 - Remote Wellness Tools and Disease Management

12 mins; November 05, 2022

S3-E52.2 - Efficacy of NITs and Predictive Outcomes

12 mins; November 05, 2022

S3-E52.1 - FIB-4 and the Way Forward in Primary Care Screening

12 mins; November 05, 2022

S3-E52 - Part 2: A Preview of the 2022 AASLD Liver Meeting

56 mins; November 02, 2022

S3-E51.5 - From the Vault: AASLD 2021 Wrap-up

12 mins; October 30, 2022

S3-E51.4 - Discussing the NAFLD-Cancer Link and Fatty Liver Awareness

11 mins; October 30, 2022

S3-E51.3 - AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity

12 mins; October 29, 2022

S3-E51.2 - Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients

13 mins; October 29, 2022

S3-E51.1 - Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial

10 mins; October 29, 2022

S3-E51 - A Preview of the 2022 AASLD Liver Meeting

47 mins; October 26, 2022

S3-E50.6 - From the Vault: Digital Health and Patient Empowerment: a Conversation with Dr. Marcus Ranney

27 mins; October 23, 2022

S3-E50.5 - FIB-4 as a Front-Line Tool for Primary Care Triage

10 mins; October 23, 2022

S3-E50.4 - Economics and Challenges of Pathway Design

9 mins; October 23, 2022

S3-E50.3 - Patient Input for Clinical Care Pathways and Guidelines

10 mins; October 22, 2022

S3-E50.2 - The Future of Digital Therapeutics and Patient Wellness Tools

10 mins; October 22, 2022

S3-E50.1 - Patient Needs and Inputs for Trial Design

12 mins; October 22, 2022

S3-E50 - Focus on Patient Advocacy

62 hours 48 mins; October 19, 2022

S3-E49.5 - From the Vault: The NICE Draft Guidance vs. The Economics of NAFLD: A Bad Fit

14 mins; October 16, 2022

S3-E49.4 - Delivering Meaningful Liver Test Results to Patients

12 mins; October 16, 2022

S3-E49.3 - Linking Liver Outcomes and Socioeconomic Status

13 mins; October 15, 2022

S3-E49.2 - Cancer vs Liver Disease Management: Political Pressures and Metaphorical Issues

14 mins; October 15, 2022

S3-E49.1 - NICE on FibroScan for Primary Care

14 mins; October 15, 2022

S3-E49 - NICE and VCTE Use in Community Settings

59 mins; October 13, 2022

S3-E48.6 - From the Vault: Themes From NASH-TAG 2022: Insights on Combination Therapies

19 mins; October 09, 2022

S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept

10 mins; October 09, 2022

S3-E48.4 - Promising Interim Data from Axcella’s Phase 2B EMMPACT Study

10 mins; October 09, 2022

S3-E48.3 - More Positive Phase 2B Results from Poxel

13 mins; October 08, 2022

S3-E48.2 - Phase 2B 'Wow!' Results from Akero’s HARMONY Trial

14 mins; October 08, 2022

S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide

12 mins; October 08, 2022

S3-E48 - Review of Exciting Clinical Trial Press Releases

59 mins; October 05, 2022

S3-E47.6 - From the Vault: Most important Story of Summer: Ian Rowe says “FDA ELF Approval”

23 mins; October 02, 2022

S3-E47.5 - Combination NIT Biomarkers and Developing a Viable System for Treating Patients

11 mins; October 02, 2022

S3-E47.4 - Potential Bottlenecks in Getting Drugs to NAFLD Patients

12 mins; October 02, 2022

S3-E47.3 - Implications of Positive Drug Trials and Eventual Approvals on NAFLD Treatment

12 mins; October 01, 2022

S3-E47.2 - The role of multiple biomarker tests in the diagnostic process

12 mins; October 01, 2022

S3-E47.1 - Collaborative energies shifting the force around Fatty Liver

12 mins; October 01, 2022

S3-E47 - What does the next year hold for the NAFLD-metabolic disease link?

57 mins; September 28, 2022

S3-E46.6 - From the Vault: Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?

11 mins; September 25, 2022

S3-E46.5 - Discussing NITs and Final Thoughts on NAFLD Summit

16 mins; September 25, 2022

S3-E46.4 - Weight Change and Lifestyle Modification in Clinical Trials

6 mins; September 25, 2022

S3 E46.3 - Discussing Clinical Trial Design at the NAFLD Summit

10 mins; September 24, 2022

S3-E46.2 - NAFLD Summit in Context and Learning from Failed Trials

12 mins; September 24, 2022

S3-E46.1 - Underreported Alcohol Use and Treating Comorbidities

12 mins; September 24, 2022

S3-E46 - A Review of the 2022 NAFLD Summit from Dublin

55 mins; September 21, 2022

S3-E45.5 - From the Vault: What Can NAIL-NIT Retrospective Analysis Tell Us About NASH?

12 mins; September 19, 2022

S3-E45.4 - Paris Review: NITs, Metabolic Disease and Final Thoughts

12 mins; September 19, 2022

S3-E45.3 - Paris Review: Session 5 on Clinical Trial Innovation

13 mins; September 19, 2022

S3-E45.2 - Paris Review: Opening and Closing Sessions

15 mins; September 19, 2022

S3 E45.1 - Paris Review: Regulator Response and "Dynamic Tension”

19 mins; September 19, 2022

S3-E45 - A Review of Paris NASH 2022 with Jeff McIntyre

62 hours 28 mins; September 14, 2022

S3-E44.6 - From Inside the Vault: Connecting the Dots at Paris NASH 2021

55 mins; September 11, 2022

S3-E44.5 - Roger Green and Jeff Lazarus Discuss on NAFLD Summit

17 mins; September 11, 2022

S3-E44.4 - Roger Green and Jeff Lazarus discuss NAFLD Nomenclature Conference and COVID-19

10 mins; September 11, 2022

Click here to see more

Surfing the MASH Tsunami

Useful pages

Find a tutor

Languages